The researchers designed a system that made it possible to inject highly concentrated drug formulations subcutaneously while reducing the required injection force, which exceeded what is possible with manual subcutaneous injection using a conventional syringe.
Humidity levels of at least 40% in public buildings and public transport would not only reduce the impact of COVID-19, but also that of other viral diseases such as seasonal influenza. Authorities should incorporate the humidity factor into future guidelines for interiors.
It is useful to combine in vitro testing and in silico modelling to predict and understand the in vivo performance of formulations that improve bioavailability, resulting in a successful in vivo test for belinostat. The key factor for in vivo performance was determined to be dissolution in the stomach prior to transit in the proximal small intestine, as evidenced by in vitro data and in silico predictions.
Water activity (Aw) is a measure of the activity of free or unbound water that is available to participate in undesirable chemical, physical and biological reactions. Measurement of water activity at multiple time points during the product life cycle will be related to changes in critical quality attributes such as degradation of the active ingredient, changes in the rate of dissolution or disintegration and changes in physical properties such as hardness or friability. Controlling water content in oral solid dose products (OSD) and dry pharmaceutical products in general, is essential to maintain efficacy and safety.
Bempedoic acid is a new class of nonstatin LDL-lowering therapy that has been approved for the European market since April 2020. Bempedoic acid can be used as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease requiring additional lowering of LDL-C.
The use of a polymer-based system reduces the risk of an undesirable chemical change in the drug product, or absorption of the drug product into the container, thereby reducing the dosage.
Polypharma has developed a cream containing the active ingredients fusidic acid and betamethasone. While fusidic acid is known to help with bacterial infections of the skin, betamethasone helps with skin diseases such as psoriasis, neurodermatitis and hives. It is well known that in patients with neurodermatitis, bacteria often occur on the skin, causing inflammation and worsening the course of the disease. In addition to neurodermatitis, this dual-therapy helps to reduce the bacteria and thus to bring the course of the disease back into balance.
New antitumor drug for Prostate Cancer
It halts metastasis and drug resistance; these are the two big problems overcome by a new antitumor drug for prostate cancer.
The drug known as DpC inhibits prostate-specific antigen (PSA), in addition to suppressing both androgen-dependent and independent androgen receptor signalling arms.
Another important aspect of the paper was the discovery that DpC could significantly reduce the expression of the well-known prostate-specific antigen specific indicator – PSA.
Novel Drug Target For Pancreatic Cancer
A new target drug, a protein called PPP1R1B, blocks the deadly spread of pancreatic cancer when inhibited in mice.
Scientists have created mice with pancreatic tumors that do not produce HIF1A. It was the levels of a protein called PPP1R1B that made the tumors more aggressive.
So they continue with drug screenings that try to identify compounds that inhibit PPP1R1B.
Salmon Calcitonin is currently administered by injection for the treatment of osteoporosis in postmenopausal women. An oral dosage form is not available due to its poor oral bioavailability. Scientists have applied technologies to overcome duodenal and sublingual biological barriers.
Everything remains in the animal PK phase and this shows that the macromolecule has great potential for oral delivery.
Rapid and adaptable evaluation of monoclonal antibody therapeutics using the Fc receptor panel test based on Octet System before selection of the final molecule.
The Octet system optimises itself for each new mAb, optimising the buffer and background conditions, thus minimising any non-specific interactions that might occur. Once this is done, it is necessary to optimise the association and dissociation times of the receptors with that antibody.
Accuracy and optimisation are the points required before arriving at the GMP test.
This system is fully compliant with CFR Part 11, and can easily be used for the Fc receptive panel test as a quantitative system, which is like a variant of ELISA (Enzyme-linked Immunosorbent Assay)